NICE backs Akcea's Tegsedi; EMA restricts Lemtrada use while it probes safety concerns
→ UK’s NICE has endorsed the use of Akcea’s inotersen (branded as Tegsedi) to treat patients with a rare inherited condition called hereditary transthyretin …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
